Zantac Litigation Group
Ranitidine, or Zantac, is a commonly used drug to treat heartburn. Zantac has been available since 1983 and was approved for over the counter use in 1995. Unfortunately, recent studies by the FDA have revealed that Zantac may contain extremely high levels of NDMA, which is known to cause liver, stomach, digestive tract, colorectal, bladder, prostate, and pancreatic cancer. Formed in 2020, the Zantac Litigation Group assists AAJ members litigating these cases.
The group formed in 2020.
- Meetings: The group meets at AAJ Annual and Winter conventions.
- Membership: The group is limited to AAJ Regular, Life, Sustaining, and President’s Club members only.
- Annual Dues: The Litigation Group is complementary to members of the AAJ Pharmaceutical and Medical Device Section who can agree to the terms and conditions of membership in the Litigation Group's Affidavit. If you are not yet a member, you can join the Pharmaceutical and Medical Device Section here.
Cochairs
Marlene Goldenberg | Nigh Goldenberg Raso & Vaughn, Washington, DC
George Williamson | Farr Farr Emerich Hackett & Carr, PA, Punta Gorda, FL
Daniel Nigh | Nigh Goldenberg Raso & Vaughn, Gulf Breeze, FL
Jennifer Moore | Moore Law Group, PLLC, Louisville, KY
R. Brent Wisner | Wisner Baum LLP, Los Angeles, CA
Litigation Group members, visit AAJ's Community Center to connect with your colleagues on the list server, search discussion archives, download documents, update your list server settings, and more. Lit Group Member Login
